Your browser doesn't support javascript.
loading
Would hyperbaric oxygen therapy be a supportive treatment method for refractory idiopathic granulomatous mastitis?
Turhan, Nihan; Sümen, Selin Gamze; Zaman, Taylan; Memisoglu, Ecem; Yilmaz, Kerim Bora.
Affiliation
  • Turhan N; Sancaktepe Martyr Prof.Dr. Ilhan Varank Training and Research Hospital, General Surgery, Turkey. Electronic address: drnihanturhan@yahoo.com.
  • Sümen SG; Kartal Lütfi Kirdar City Hospital, Underwater Medicine and Hyperbaric Medicine, Turkey.
  • Zaman T; Gülhane Training and Research Hospital, Underwater Medicine and Hyperbaric Medicine, Turkey.
  • Memisoglu E; Kartal Lütfi Kirdar City Hospital, General Surgery, Turkey.
  • Yilmaz KB; Gülhane Training and Research Hospital, General Surgery, Turkey.
Asian J Surg ; 2024 May 03.
Article de En | MEDLINE | ID: mdl-38704271
ABSTRACT

BACKGROUND:

Refractory IGM causes patients to use antibiotics, steroid therapy, immunosuppressive agents for a very long time and even leads to surgical procedures resulting in the loss of breast tissue. Hyperbaric Oxygen Therapy (HBOT) is a frequently used method in the treatment of wounds that are difficult to heal. We thought that HBOT would be an alternative treatment method for refractory IGM patients.

METHODS:

It is a retrospective cohort study on refractory IGM patients conducted at three tertiary care treatment centers between January 2021 and July 2023. The patients were evaluated in two groups those who only took steroid treatment and those who received HBOT and steroid treatment. The demographic and clinical characteristics of the patients, the types of treatment applied and their responses to treatment were evaluated.

RESULTS:

There were no significant differences generally in the demographic and clinical features in both groups. The incidence of multicentric GM was found to be higher in the HBOT group (66.67 %; p = 0.044). Although the recovery results were similar in both groups, the average daily steroid dose and duration of drug use were found to be higher in the group receiving only steroid treatment (16 mg vs. 4 mg and 270 days vs. 30 days) (p < 0.001).

CONCLUSION:

In our study, we showed for the first time in the literature that HBOT is effective in the treatment of refractory IGM patients. Our study needs to be supported by prospective studies evaluating cost effectiveness and possible long term complications.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Asian J Surg Année: 2024 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Asian J Surg Année: 2024 Type de document: Article